+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of ONO-2020 in treating agitation associated with Alzheimers Disease dementia in patients aged 55 to 90 years in Japan. This phase 2a, multicenter, randomized, double-blind, placebo-controlled study aims to better understand how ONO-2020 affects agitation symptoms in this population. Participants will be randomly assigned to receive either two tablets of ONO-2020 or matching placebo once daily. This treatment will continue for up to 12 weeks, with monitoring of safety and efficacy measures during and up to 16 weeks from the start. The study includes close observation for adverse events and vital signs, as well as laboratory and ECG monitoring. Throughout the trial, participants will undergo assessments including agitation severity using the Cohen-Mansfield Agitation Inventory CMAI, cognitive function tests like the Mini Mental State Exam MMSE, and neuropsychiatric evaluations. Safety will be monitored through vital signs, ECGs, laboratory tests, and the Columbia-Suicide Severity Rating Scale. The total participation period covers up to 16 weeks, including treatment and follow-up assessments.

Age: 55Years - 90YearsAll GendersPhase 2
39 locations
C

Actively Recruiting

Researchers are comparing overall survival in patients with advanced biliary tract cancer receiving different treatment combinations. This phase 3 international study evaluates Futibatinib and Zimberelimab combined with Gemcitabine plus Cisplatin against Durvalumab or Pembrolizumab combined with Gemcitabine plus Cisplatin as first-line therapy for these patients. The study aims to assess which treatment approach may provide better outcomes for this advanced cancer type. Participants will be assigned to one of two groups one receiving Futibatinib orally once daily together with Zimberelimab by intravenous infusion every three weeks, plus Gemcitabine and Cisplatin given intravenously on Days 1 and 8 of each three-week cycle the other group will receive either Durvalumab or Pembrolizumab by intravenous infusion every three weeks alongside Gemcitabine and Cisplatin on the same schedule. Treatments continue with these cycles as per study protocol. During the study, participants will be regularly assessed for overall survival up to approximately 45 months. Additional evaluations include progression-free survival, tumor response rates, duration of response, and monitoring of adverse events. These assessments will be conducted through imaging, biomarker analysis, and clinical examinations to understand treatment effects and safety over time.

Age: 18Years +All GendersPhase 3
21 locations
I

Actively Recruiting

Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.

All AgesAll Genders
54 locations